<DOC>
	<DOCNO>NCT00005948</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy . PURPOSE : Phase II trial study effectiveness chemotherapy follow peripheral stem cell transplantation biological therapy treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Transplantation And Biological Therapy Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity high-dose busulfan follow interleukin-2 ( IL-2 ) sargramostim ( GM-CSF ) activate autologous/syngeneic peripheral blood stem cell ( PBSC ) transplantation , sequential IL-2 GM-CSF therapy , interferon alfa patient chronic myelogenous leukemia . II . Determine engraftment potential IL-2/GM-CSF activate PBSC follow sequential IL-2/GM-CSF therapy patient population . III . Assess time cytogenetic and/or morphologic relapse , overall event-free survival , overall survival patient treat regimen . OUTLINE : Autologous peripheral blood stem cell ( PBSC ) harvest activate interleukin-2 ( IL-2 ) sargramostim ( GM-CSF ) another protocol . Patients receive oral busulfan every 6 hour day -6 -3 total 16 dos . IL-2 GM-CSF-activated PBSC reinfused day 0 . Beginning 4 hour PBSC infusion , patient receive IL-2 IV continuously 5 day follow 2 day rest 4 week . In addition , GM-CSF administer subcutaneously ( SC ) every Monday , Wednesday , Friday 4 week . Upon hematologic recovery , earlier 2 week IL-2 GM-CSF , patient receive interferon alfa SC 3 time weekly clear evidence disease progression . Patients follow every 6 month 3 year annually thereafter . PROJECTED ACCRUAL : A total 25 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Chronic myelogenous leukemia previously store CD34 cell FHCRC928.00 Chronic phase : No evidence major response 6month course interferon alfa OR Initially achieve major cytogenetic response subsequently fail interferon alfa OR Accelerated phase : At least 1 month collection peripheral blood stem cell No blast crisis No CNS involvement Ineligible refuse allogeneic conventional minitransplant protocol PATIENT CHARACTERISTICS : Age : 70 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL ( unless history Gilbert 's disease ) AST ALT great 2.5 time upper limit normal No cirrhosis Hepatitis B C negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 12 month No unstable angina , poorly control arrhythmia , hypertension LVEF great 50 % Pulmonary : DLCO least 50 % Alveolar arterial gradient le 30 sea level Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active infection require systemic antibiotic No know allergy gentamicin murine E. coli protein document prior anaphylactic reaction sargramostim ( GMCSF ) interleukin2 PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : No concurrent ongoing steroid Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
</DOC>